PUBLIC COMPANY
save$VIRVir Biotechnology, Inc.
$VIR9.1500-1.08%San Francisco, CA, USupdated 14h ago
community read0 votes
pipeline
5
marketed
0
phase 3
3
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(5)
pipeline depth5 products
2Phase 13Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase3A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection
- phase1Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
- phase1A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218
- phase2Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection
- phase2Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection
- phase1Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
- phase3A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide
- phase2A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection
🐶 Hiring Signal
News
- BioSpace 2027 Best Places to Work shines light on most admired employersThe list honors 50 life sciences employers of choice. Employees at SERB Pharmaceuticals and CSL Behring share why their companies stand out.biospace · 9d ago
- Gilead’s ‘highly competitive’ mid-stage ulcerative colitis data ‘validate’ I&I pushGilead’s emvistegrast delivered greater clinical response than placebo, setting up the asset for Phase 3 testing in ulcerative colitis as well as studies in other inflammatory diseases and bolsteri…biospace · 1mo ago
Data sources
last refreshed 44m ago
Found something off?
comments(0)
5-min edit window · permanent after that